In this work, we demonstrated an involvement of the HSP70/HSF1 axis in ibrutinib-resistance in chronic lymphocytic leukemia (CLL), and the effect of the inhibition of this axis as a basis for identifying new strategies in CLL treatment. This evidence concerns the gene HSF1 and B-cell chronic lymphocytic leukemia.